Related Experiment Videos
Hyperparathyroidism and bone disease after renal transplantation
Drasko Pavlović1, Lidija Orlić
1Sveti Duh General Hospital, Sveti Duh 64, HR-10000 Zagreb. drasko.pavlovic@bol-svduh.hinet.hr
Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
|February 25, 2003
Summary
Successful kidney transplants can reverse metabolic bone disease, but some issues like high parathyroid hormone may persist. Immunosuppressants can worsen bone loss, necessitating treatments like bisphosphonates and calcitriol.
Area of Science:
- Nephrology
- Endocrinology
- Orthopedics
Background:
- Metabolic bone disease is a common complication of chronic kidney disease.
- Renal transplantation often resolves these bone disorders.
- Persistent bone abnormalities and drug-induced bone loss can occur post-transplant.
Purpose of the Study:
- To review the impact of renal transplantation on metabolic bone disease.
- To discuss persistent bone disorders post-transplant.
- To highlight the role of immunosuppressive drugs and preventive therapies.
Main Methods:
- Literature review of metabolic bone disease in renal failure and post-transplantation.
- Analysis of persistent endocrine and bone metabolic changes.
- Evaluation of pharmacological interventions for bone disease prevention.
Main Results:
- Successful transplantation reverses many bone disorders.
- Increased parathyroid hormone secretion can persist post-transplant.
- Immunosuppressive drugs contribute to bone mass reduction.
Conclusions:
- Bone health management is crucial after renal transplantation.
- Bisphosphonates and calcitriol are key in preventing post-transplant bone disease.
- Continued monitoring and treatment are necessary for optimal bone health.